质子或光子放疗后脑膜瘤患者的放射性脑损伤
本研究回顾性比较质子与光子放疗治疗脑膜瘤后影像学及临床不良事件发生率。77例患者中质子组38例、光子组39例,中位随访2.2年。两组症状性不良事件及生存无显著差异,但质子组T1c+T2改变2年累积发生率显著高于光子组。
要点
- 质子与光子放疗后症状性不良事件及生存无显著差异
- 质子组T1c+T2影像改变2年累积发生率显著高于光子组
- 两组严重不良事件均少见,T2改变总体发生率较高
核心结论
- 质子放疗与光子放疗后脑膜瘤患者症状性不良事件及生存相当,但质子组T1c+T2影像改变发生率显著更高。
研究设计与样本
- 回顾性研究,纳入两家高容量三级癌症中心接受质子或光子放疗的脑膜瘤患者77例,质子组38例、光子组39例。
主要发现
- 症状性不良事件≥2级在质子组4例(10.5%)、光子组3例(7.7%),p=0.67。
- T2改变2年累积发生率质子组38.3%、光子组47.7%,p=0.53。
- T1c+T2改变2年累积发生率质子组26.8%、光子组5.3%,p=0.02。
- 每组各1例发生≥4级不良事件,p=0.99。
- 2年无进展生存率79.5%(质子组76.0% vs 光子组81.3%,p=0.66),2年总生存率89.7%(质子组86.6% vs 光子组89.3%,p=0.65)。
临床怎么用
- 脑膜瘤放疗后应关注MRI T2及T1c+T2影像改变,质子放疗者T1c+T2改变发生率更高。
- 质子与光子放疗后严重不良事件及生存相当,选择放疗方式时需综合评估影像学改变风险。
局限性
- 回顾性研究,样本量较小(共77例),中位随访仅2.2年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Radiation therapy is often used to treat meningioma with adverse features or when unresectable. Proton therapy has advantages over photon therapy in reducing integral dose to the brain. This study compared the incidence of radiological and clinical adverse events after photon versus proton therapy in the treatment of meningioma. METHODS: A retrospective review was conducted on patients with meningioma treated with proton or photon therapy at two high-volume tertiary cancer centers. Patients with a history of prior radiation therapy (RT) or less than 3 months of follow-up were excluded. Post-RT imaging changes were categorized into abnormal T2 signal intensities (T2 changes) or abnormal T1 post-contrast and T2 signal intensities (T1c+T2 changes) on magnetic resonance imaging (MRI). Clinical outcomes of adverse events and survival were compared between the proton and photon therapies. RESULTS: Among the total of 77 patients, 38 patients received proton therapy and 39 patients received photon therapy. The median age at diagnosis was 55 years and median follow-up was 2.2 years. No significant differences in symptomatic adverse events were observed between the two groups: grade ≥ 2 adverse events were seen in 4 (10.5%) patients in the proton group and 3 (7.7%) patients in the photon group (p = 0.67). The 2-year cumulative incidences of T2 changes were 38.3% after proton therapy and 47.7% after photon therapy (p = 0.53) and the 2-year cumulative incidences of T1c+T2 changes were 26.8% after proton therapy and 5.3% after photon therapy (p = 0.02). One patient experienced grade ≥ 4 adverse event in each group (p = 0.99). Estimated 2-year progression-free survival was 79.5% (proton therapy 76.0% vs. photon therapy 81.3%, p = 0.66) and 2-year overall survival was 89.7% (proton therapy 86.6% vs. photon therapy 89.3%, p = 0.65). CONCLUSIONS: Following RT, high rates of T2 changes were seen in meningioma patients regardless of treatment modality. Proton therapy was associated with significantly higher rates of T1c+T2 changes compared with photon therapy, but severe adverse events were uncommon in both groups and survival outcomes were comparable between the two groups. Future studies will aim at correlating the MRI changes with models that can be incorporated into RT planning to avoid toxicity.
引用
- Song J, Aljabab S, Abduljabbar L, et al. Radiation-induced brain injury in patients with meningioma treated with proton or photon therapy. J Neurooncol. 2021. PMID: 33886111. doi:10.1007/s11060-021-03758-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。